Mathias Witzens-Harig - JoVE Visualize

Showing results (61-70 of 80) with videos related to

Pageof 8

Sort By:

Annals of Hematology|May 15, 2014

Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA studyMathias Witzens-Harig, Robin Foá, Alice Di Rocco, et al.

Hemasphere|July 11, 2020

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular LymphomaGeorg Hess, Karola Wagner, Ulrich Keller, et al.

British Journal of Haematology|October 10, 2015

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trialMathias Witzens-Harig, Axel Benner, Fabienne McClanahan, et al.

British Journal of Haematology|April 1, 2022

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.

Hemasphere|September 30, 2021

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM TrialMathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.

Leukemia & Lymphoma|October 20, 2021

Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study groupMichael Pfreundschuh, Viola Poeschel, Samira Zeynalova, et al.

Blood|April 23, 2013

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6Mathias Witzens-Harig, Dirk Hose, Simone Jünger, et al.

Investigational New Drugs|March 16, 2020

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.

Hemasphere|November 15, 2019

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR StudyKlaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.

Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:

Pageof 8

Annals of Hematology|May 15, 2014

Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA studyMathias Witzens-Harig, Robin Foá, Alice Di Rocco, et al.

Hemasphere|July 11, 2020

Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular LymphomaGeorg Hess, Karola Wagner, Ulrich Keller, et al.

British Journal of Haematology|October 10, 2015

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trialMathias Witzens-Harig, Axel Benner, Fabienne McClanahan, et al.

British Journal of Haematology|April 1, 2022

A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialGeorg Hess, Andreas Hüttmann, Mathias Witzens-Harig, et al.

Hemasphere|September 30, 2021

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM TrialMathias Witzens-Harig, Andreas Viardot, Ulrich Keller, et al.

Leukemia & Lymphoma|October 20, 2021

Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trialDominic Kaddu-Mulindwa, Vadim Lesan, Christian Berdel, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2014

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study groupMichael Pfreundschuh, Viola Poeschel, Samira Zeynalova, et al.

Blood|April 23, 2013

Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6Mathias Witzens-Harig, Dirk Hose, Simone Jünger, et al.

Investigational New Drugs|March 16, 2020

Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.

Hemasphere|November 15, 2019

Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR StudyKlaus Herfarth, Peter Borchmann, Sven Schnaidt, et al.

Pageof 8